We also demonstrated that the inhibition of UMPS-mediated cell death induced by the combination treatment is determined by the genetic status of p53 in lung cancer cells, indicating the importance of p53 in UMPS-dependent metabolism. Here, TP53 is linked to lung carcinoma.